The Pharmaceutical Journal
Vol 279 No 7465 p174
18 August 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Veralipride withdrawal

The European Medicines Agency (EMEA) has recommended the withdrawal of medicines containing veralipride following a safety review that indicates its side effects outweigh its limited efficacy (PDF 50K).

The drug, a treatment for hot flushes associated with the menopause, is available in Belgium, France, Italy, Luxembourg and Portugal.

The EMEA says that treatment should not be stopped abruptly but should be reduced gradually.